We are live on
!
Find out more
SEC
Seven Eight Capital Portfolio holdings
AUM
$1.11B
1-Year Est. Return
29.48%
This Fund
S&P 500
This Quarter
Est. Return
+6.96%
1 Year Est. Return
+29.48%
3 Year Est. Return
+13.61%
5 Year Est. Return
+117.69%
10 Year Est. Return
+239.1%
AUM
$342M
AUM Growth
+$51.1M
(+18%)
Cap. Flow
+$47.6M
Cap. Flow
% of AUM
13.91%
Top 10 Holdings %
Top 10 Hldgs %
10.44%
Holding
675
New
141
Increased
130
Reduced
57
Closed
344
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceuticals
TEVA
|
+$4.02M |
| 2 |
Nike
NKE
|
+$3.8M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$3.69M |
| 4 |
BNY
Bank of New York Mellon
BNY
|
+$3.63M |
| 5 |
Costco
COST
|
+$3.41M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
PNC Financial Services
PNC
|
+$3.04M |
| 2 |
Visa
V
|
+$2.98M |
| 3 |
Procter & Gamble
PG
|
+$2.96M |
| 4 |
PXD
Pioneer Natural Resource Co.
PXD
|
+$2.94M |
| 5 |
CPGX
COLUMBIA PIPELINE GROUP IN COM STK (DE)
CPGX
|
+$2.82M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 15.97% |
| 2 | Industrials | 12.49% |
| 3 | Consumer Discretionary | 11.9% |
| 4 | Healthcare | 11.63% |
| 5 | Consumer Staples | 10.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
PE
226
DELISTED
PARSLEY ENERGY INC
PE
| $422K | 0.12% |
+12,600
| New | +$394K |
|
227
CVS Health
CVS
$136B
| $413K | 0.12% |
4,643
-14,500
| -76% | -$1.37M |
|
228
Align Technology
ALGN
$13B
| $403K | 0.12% |
4,300
+400
| +10% | +$36.2K |
|
229
Eastman Chemical
EMN
$7.71B
| $402K | 0.12% |
5,939
-1,100
| -16% | -$73.8K |
|
230
Automatic Data Processing
ADP
$111B
| $399K | 0.12% |
+4,520
| New | +$410K |
|
|
TECD
231
DELISTED
Tech Data Corp
TECD
| $396K | 0.12% |
+4,680
| New | +$362K |
|
|
PPLI
232
People Inc
PPLI
$3.15B
| $390K | 0.11% |
+34,971
| New | +$369K |
|
|
CBPO
233
DELISTED
China Biologic Products Holdings, Inc.
CBPO
| $386K | 0.11% |
3,100
+2,200
| +244% | +$260K |
|
234
Microchip Technology
MCHP
$39.9B
| $385K | 0.11% |
+12,398
| New | +$360K |
|
|
EVER
235
DELISTED
Everbank Financial Corp
EVER
| $385K | 0.11% |
+19,900
| New | +$360K |
|
236
KeyCorp
KEY
$24.1B
| $381K | 0.11% |
31,288
-184,112
| -85% | -$2.2M |
|
|
WFT
237
DELISTED
Weatherford International plc
WFT
| $374K | 0.11% |
66,511
+42,000
| +171% | +$239K |
|
|
XYZ
238
Block Inc
XYZ
$49.5B
| $365K | 0.11% |
+31,300
| New | +$342K |
|
239
Cinemark Holdings
CNK
$4.09B
| $364K | 0.11% |
+9,500
| New | +$360K |
|
|
FLG
240
Flagstar Bank National Association
FLG
$5.91B
| $361K | 0.11% |
+8,458
| New | +$372K |
|
241
Lam Research
LRCX
$324B
| $360K | 0.11% |
38,030
-27,000
| -42% | -$246K |
|
242
Allegion
ALLE
$13.5B
| $358K | 0.1% |
+5,200
| New | +$366K |
|
|
OA
243
DELISTED
Orbital ATK, Inc.
OA
| $358K | 0.1% |
4,696
-1,500
| -24% | -$119K |
|
244
Arch Capital
ACGL
$36.5B
| $357K | 0.1% |
13,500
+9,000
| +200% | +$229K |
|
245
Credicorp
BAP
$30.7B
| $353K | 0.1% |
+2,316
| New | +$365K |
|
246
Texas Roadhouse
TXRH
$13.7B
| $351K | 0.1% |
+9,000
| New | +$403K |
|
|
EVHC
247
DELISTED
Envision Healthcare Holdings Inc
EVHC
| $350K | 0.1% |
+5,246
| New | +$361K |
|
248
Synaptics
SYNA
$4.21B
| $349K | 0.1% |
5,963
+2,500
| +72% | +$137K |
|
|
LOGM
249
DELISTED
LogMein, Inc.
LOGM
| $343K | 0.1% |
+3,800
| New | +$304K |
|
250
Lincoln National
LNC
$8.06B
| $338K | 0.1% |
7,200
-2,700
| -27% | -$121K |
|
Similar funds
PP
ECM
GCAC
CAM
D
GFS
FTIS
AIA
Seven Eight Capital's Q3 2016 Portfolio in Review
As of Q3 2016, Seven Eight Capital held 675 positions worth $342M, up 18% from $291M the previous quarter. Its ten largest holdings account for 10% of the portfolio.
Seven Eight Capital deployed $47.6M of net new capital in Q3 2016, opening 141 new positions and adding to 130 existing holdings. Its largest new stake was Teva Pharmaceuticals: 77,100 shares worth $3.55M.
By sector, the portfolio is most concentrated in Technology at 16% of assets, down from 17% a quarter earlier, followed by Industrials and Consumer Discretionary.
On the sell side, the largest reduction was Mastercard, an estimated $2.55M trimmed.
- Seven Eight Capital's largest Q3 2016 buy was Teva Pharmaceuticals: 77,100 shares worth $3.55M.
- Seven Eight Capital added most to Bristol-Myers Squibb in Q3 2016, an estimated $3.69M increase.
- Seven Eight Capital's biggest Q3 2016 reduction was Mastercard, cutting an estimated $2.55M.
- Seven Eight Capital fully exited PNC Financial Services in Q3 2016, selling an estimated $3.04M.
- Seven Eight Capital's ten largest holdings make up 10% of its $342M portfolio in Q3 2016.
- Seven Eight Capital opened 141 new positions and closed 344 in Q3 2016.
- Seven Eight Capital's portfolio value rose 18% quarter-over-quarter to $342M.
Based on Seven Eight Capital's 13F filing for Q3 2016, filed 14 Nov 2016.